September 10, 2018

Cyclenium Pharma and Haplogen Biosciene Announce Announce Granting of EUREKA Label and Funding to Develop Novel Therapies in Severe Viral Diseases.

See Press Release (DE version

August 14, 2018

BAYER and HAPLOGEN form a collaboration to develop new therapeutics for patients suffering from pulmonary diseases

See Press Release (DE version)

January 12, 2017

Biological Mechanism of Haplogen’s Novel Antiviral Target published in “Nature”

See Press Release (DE version)

May 7, 2015

Cyclenium Pharma and Haplogen Announce Drug Discovery Collaboration

See Press Release

January 8, 2015

Horizon Discovery acquires Haplogen Genomics GmbH

See Press Release

February 12, 2014

Horizon Discovery and Haplogen announce a partnership to co-market Haplogen’s Haploid Gene Trap Mutant Collection.

See Press Release

August 25, 2013

Haplogen and CeMM report the world’s largest collection of engineered human cell lines for biomedical discovery in Nature Methods.

Also see articles in NatureThe Scientist and SciBX

May 8, 2013

Founder Thijn Brummelkamp receives the EMBO Gold Medal 2013 for "his outstanding work to accelerate the genetic analysis of human disease", including the development of haploid genetics. 

Also see article in Nature.

December 17, 2012

Haplogen is featured in BioCentury: Mining for host factors. 

November 15, 2012

Haplogen partners with Evotec to develop drugs for infectious diseases. 

See Press Release